Covid19 Clinical Trial
Official title:
A Phase 2, Randomized, Double Blinded, Placebo Controlled, Parallel Group, Single Administration Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19
This is a Phase 2 prospective, randomized, placebo-controlled, double-blinded, parallel group, single administration, multi-center study to assess the safety and efficacy of efineptakin alfa single treatment compared to placebo in elderly participants (adults ≥50years) with asymptomatic or mild COVID-19
Status | Recruiting |
Enrollment | 210 |
Est. completion date | September 2021 |
Est. primary completion date | June 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: 1. Adults aged 50 years and above at the time of consent 2. Subjects who have been confirmed to be COVID-19 corresponding to asymptomatic case or mild cases of severity categorization classified by FDA through authorized molecular saliva-based test or polymerase chain reaction (PCR) test and who can be available to be administered within 7 days from the onset of any symptoms. 3. Patients who provide a voluntarily consent to participate in the study and sign the consent form in his/her own handwriting. 4. Female patients of childbearing potential (including female received a tubal ligation) should be prove negative pregnancy through pregnancy test before 24 hours of the IP administration, and must be willing to maintain abstinence (restraint sexual relationships) or use an adequate method of contraception at least 90 days after the IP administration. 5. Male patients must be willing to maintain abstinence (restraint sexual relationships) or use of adequate contraception method, and not to donate sperm. Men with childbearing or pregnant female spouses should maintain abstinence or use condoms at least 90 days after the IP administration to avoid exposure to embryos 6. Patients who agree for the hospitalisation (however, the hospitalisation will be performed only if needed) Exclusion Criteria: 1. Patients who are unable to follow clinical and follow-up procedures 2. Patients with symptoms of moderate or higher in the severity classification presented by FDA have evidence of lower respiratory tract infection in their imaging findings or need supplemental oxygen therapy or mechanical respiration (ie, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, etc) 3. Patients who have clinically significant cardiovascular diseases such as myocardial infarction, unstable arrhythmia and/or unstable angina within 3 months 4. Patients who have uncontrolled type II diabetes mellitus (despite the proper use of the drug, if fasting blood sugar level is not controlled to be more than 200 mg/dL) 5. If the principal investigator determines that patients are ineligible or difficult to follow the protocol due to evidence of severe or unregulated systemic diseases, uncontrolled hypertension (despite the proper use of the drug, if the blood pressure is not controlled to be lower than 150/90 mmHg), and active bleeding tendency 6. Patients who are known to be HIV positive 7. Patients who are known to be B-type, or C-type hepatitis-positive carrier 8. Patients who are pregnant or breastfeeding 9. Patients suspected of or identified with a malignant tumor or have a history of tumors within the past 5 years 10. Patients with the infectious diseases such as bacteremia or severe pneumonia requiring active treatment within four weeks prior to the IP administration 11. Patients with immunodeficiency or autoimmune diseases that can be exacerbated through immunotherapy at present 12. Patients who have previously received an allogeneic marrow transplantation or solid organ transplantation 13. Patients who are currently taking other drugs such as immunosuppressants that may affect the results of the study 14. Patients who have severe allergy for humanized antibodies or fusion proteins, anaphylaxis, or other hypersensitivity 15. Patients who have received other IP administration while participating in another clinical trial within 30 days prior to the IP administration for this study (However, biological preparation shall be applied to 60 days and even longer period can be applied considering the half-life) - |
Country | Name | City | State |
---|---|---|---|
Indonesia | Mitra Keluarga Kelapa Gading | Jakarta Pusat | |
Indonesia | Mitra Keluarga Kemayoran | Jakarta Pusat |
Lead Sponsor | Collaborator |
---|---|
PT Kalbe Genexine Biologics | Genexine, Inc. |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Immune repertoire in the study population | Changes of the rate of different immune cell types (i.e, effector/ memory T cell) and regulatory T cell (i.e, Tregs) in the blood after a single efineptakin alfa treatment, if possible | 9 weeks | |
Primary | Dose finding | MTD and RP2D based on safety profiles | 9 weeks | |
Primary | Absolute lymphocyte count (ALC) | The change of absolute lymphocyte count from baseline | 9 weeks | |
Secondary | Treatment related Adverse Events | The proportion of participants with treatment emergent adverse events | 10 weeks | |
Secondary | Status of COVID-19 infection | Decrease of viral shedding identified with nasopharyngeal swab specimen by RT-PCR test | 9 weeks | |
Secondary | To evaluate the efficacy of GX-I7 in patients with COVID-19 | The proportion of participants who have progressed to moderate or severe or critical illness | 9 weeks | |
Secondary | Improvement in clinical parameters | Time to clinical improvement: clinical improvement is defined as a = 2-point improvement in clinical status (8-point ordinal scale) from Day 1 (baseline) | 9 weeks | |
Secondary | Assess in improvement in clinical parameters | Time to = 1-point improvement (days) from Day 1 (baseline) in terms of clinical status | 9 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |